David A. Siegel Tempest Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2022 Aug 15, 2022	SELL	$2.08 - $4.15 $21,008 - $41,915	-10,100 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$2.27 - $5.45 $22,927 - $55,045	10,100 New	10,100 $34,000

1.72M

30K

80.5K

Ticker TPST
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 10,418,900
Market Cap $14.3M
Description
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxiso...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.